Skip to main content

Post-Traumatic Headache

7
Pipeline Programs
11
Companies
13
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
6
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 10 programs with unclassified modality

On Market (2)

Approved therapies currently available

Eli Lilly and Company
EMGALITYApproved
galcanezumab-gnlm
Eli Lilly and Company
injection2018
PRAZOSIN HYDROCHLORIDEApproved
prazosin
Unknown Company
oral2024

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
Galcanezumab-GnlmPHASE_4
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
1
AbobotulinumtoxinAPhase 41 trial
Active Trials
NCT03928496Completed40Est. Feb 2017
Prevail Therapeutics
1 program
1
Galcanezumab-GnlmPhase 41 trial
Active Trials
NCT06901518Completed25Est. Nov 2024
Sound Pharmaceuticals
1 program
1
PrazosinPhase 41 trial
Active Trials
NCT02965027Completed89Est. Jun 2023
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
sumatriptan/naproxen sodiumPhase 4
Sandoz
SandozAustria - Kundl
1 program
1
AMG 334Phase 21 trial
Active Trials
NCT03974360Completed100Est. Dec 2019
Genomics
GenomicsUK - Oxford
2 programs
Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic HeadacheN/A1 trial
ErenumabPHASE_2Monoclonal Antibody1 trial
Active Trials
NCT04369729Completed101Est. Aug 2025
NCT04098250Completed6Est. Jan 2024
Amgen
AmgenTHOUSAND OAKS, CA
1 program
Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic HeadacheN/A
electroCore
electroCoreNJ - Rockaway
1 program
gammaCore SapphireN/A1 trial
Active Trials
NCT04071743Withdrawn0Est. Dec 2021
Teva
TevaIsrael - Petach Tikva
1 program
FremanezumabPHASE_2Monoclonal Antibody5 trials
Active Trials
NCT04041284Completed353Est. Aug 2022
NCT03347188Completed87Est. Jun 2020
NCT03107052Terminated275Est. Jun 2019
+2 more trials
Ipsen
IpsenChina - Tianjin
1 program
AbobotulinumtoxinAPHASE_4

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Prevail TherapeuticsGalcanezumab-Gnlm
TevaFremanezumab
Sound PharmaceuticalsPrazosin
Angeles TherapeuticsAbobotulinumtoxinA
TevaFremanezumab
TevaFremanezumab
TevaFremanezumab
TevaFremanezumab
GenomicsErenumab
SandozAMG 334
TevaFremanezumab
GenomicsInvestigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache
electroCoregammaCore Sapphire

Clinical Trials (13)

Total enrollment: 4,265 patients across 13 trials

NCT06901518Prevail TherapeuticsGalcanezumab-Gnlm

The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches

Start: Aug 2020Est. completion: Nov 202425 patients
Phase 4Completed
NCT04041284TevaFremanezumab

A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

Start: Sep 2019Est. completion: Aug 2022353 patients
Phase 4Completed
NCT02965027Sound PharmaceuticalsPrazosin

Prazosin for Post-Concussive Headaches

Start: Nov 2016Est. completion: Jun 202389 patients
Phase 4Completed
NCT03928496Angeles TherapeuticsAbobotulinumtoxinA

Abobotulinumtoxina Efficacy in Post-Traumatic Headache

Start: Aug 2013Est. completion: Feb 201740 patients
Phase 4Completed
NCT03107052TevaFremanezumab

A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache

Start: Apr 2017Est. completion: Jun 2019275 patients
Phase 3Terminated
NCT02945046TevaFremanezumab

A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)

Start: Jan 2017Est. completion: May 2019169 patients
Phase 3Terminated
NCT02621931TevaFremanezumab

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

Start: Mar 2016Est. completion: Apr 20171,130 patients
Phase 3Completed
NCT02638103TevaFremanezumab

Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine

Start: Feb 2016Est. completion: Dec 20181,890 patients
Phase 3Completed
NCT04098250GenomicsErenumab

Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH

Start: Jan 2021Est. completion: Jan 20246 patients
Phase 2Completed
NCT03974360SandozAMG 334

Efficacy and Tolerability of Erenumab in the Prophylactic Treatment of Persistent Post-Traumatic Headache

Start: Apr 2019Est. completion: Dec 2019100 patients
Phase 2Completed
NCT03347188TevaFremanezumab

A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)

Start: Dec 2017Est. completion: Jun 202087 patients
Phase 2Completed
NCT04369729GenomicsInvestigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache

Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache

Start: Sep 2020Est. completion: Aug 2025101 patients
N/ACompleted
NCT04071743electroCoregammaCore Sapphire

Study of Gammacore Sapphire for the Acute and Preventive Treatment of Post-Traumatic Headache (GAP-PTH)

Start: Jan 2020Est. completion: Dec 20210
N/AWithdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

11 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.